StockData

Biogen vs Gilead Sciences

BIIB and GILD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIIB and GILD compare

Gilead Sciences is the larger company, worth 5.7 times as much as Biogen ($211B against $37.1B).

Gilead Sciences grew revenue faster over the last twelve months (6.5% versus 2.3% for Biogen).

Biogen keeps more of each dollar of sales as profit, with a net margin of 3.4% compared with −12.5% at Gilead Sciences.

Gilead Sciences pays a dividend yielding 1.9%; Biogen does not pay one.

Gilead Sciences scores higher on the StockData Score (12 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIIBGILD
Size and price
Market cap$37.1B$211B
Share price$250.79$170.26
Change, 1 year49.7%36.2%
Change, 5 years3.2%142%
Beta (5Y)0.140.13
Employees7,50017K
StockData Score
Total score412 (better)
Valuation score1 (better)0
Growth score03 (better)
Performance score13 (better)
Health score23 (better)
Dividend score03 (better)
Valuation
P/E107×–
P/S3.6× (better)6.8×
P/B–16.2×
EV/EBITDA21.9×–
P/FCF17.9×15.3× (better)
FCF yield5.6%6.5% (better)
Fair value$160.54$83.55
Margin of safety−56.2% (better)−104%
Growth
Revenue growth (TTM)2.3%6.5% (better)
Revenue growth, 5Y average−6.0%3.6% (better)
Net income growth (TTM)−78.4% (better)−148%
EPS growth (TTM)−78.7% (better)−149%
EPS growth, 5Y average−18.7%132% (better)
Profitability
Gross margin74.0%79.9% (better)
Operating margin–−7.6%
Net margin3.4% (better)−12.5%
FCF margin20.1%44.5% (better)
Return on equity–−22.3%
Return on invested capital–−5.2%
Financial health
Debt / equity–2.01
Interest coverage–−2.3×
Current ratio1.95 (better)1.38
Altman Z-score3.073.94 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Dividend yield–1.9%
Years of dividend growth–11
Dividend growth, 5Y average–3.0%
Buyback yield–0.51%
Shareholder yield0.00%2.4% (better)
Ownership
Held by institutions96.2%89.8%
Held by insiders0.21%0.10%
Insider net buying, 12 months−$905K (better)−$101M
Superinvestors holding1–
Short interest, % of float3.7%1.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.